Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: a post hoc analysis of DEVOTE. 

Diabetes Technology & Therapeutics. 2023

Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. 

JAMA. 2021

The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. 

Diabetes care. 2021

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial. 

Diabetes, Obesity & Metabolism. 2018

Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. 

JAMA cardiology. 2017

Liraglutide and renal outcomes in type 2 diabetes. 

New England Journal of Medicine. 2017

Liraglutide and cardiovascular outcomes in type 2 diabetes. 

New England Journal of Medicine. 2016

Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. 

Diabetes care. 2016

Insulin dose and cardiovascular mortality in the ACCORD Trial. 

Diabetes care. 2015

LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. 

Diabetes, Obesity & Metabolism. 2015

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 

Diabetologia. 2015

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. 

Diabetes care. 2015

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial. 

Pancreas. 2014

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. 

Diabetes care. 2014

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. 

American Heart Journal. 2013

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. 

Diabetes care. 2012

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. 

Diabetologia. 2012

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 

Diabetologia. 2012

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. 

Diabetes care. 2012

Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. 

Diabetes Technology & Therapeutics. 2011

Long-term effects of intensive glucose lowering on cardiovascular outcomes. 

New England Journal of Medicine. 2011

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. 

Diabetes care. 2011

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. 

Annals of Internal Medicine. 2011

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. 

New England Journal of Medicine. 2010

Effects of combination lipid therapy in type 2 diabetes mellitus. 

New England Journal of Medicine. 2010

Effects of intensive blood-pressure control in type 2 diabetes mellitus. 

New England Journal of Medicine. 2010

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. 

Diabetes care. 2010

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. 

Diabetes care. 2010

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. 

BMJ (Clinical research ed.). 2010

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 

Lancet (London, England). 2009

Effects of intensive glucose lowering in type 2 diabetes. 

New England Journal of Medicine. 2008

Effects of intensive glucose lowering in type 2 diabetes N Engl J Med

2008

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. 

Lancet (London, England). 2008

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. 

Diabetes care. 2005

Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. 

Current Medical Research and Opinion. 2004

The insulin resistance syndrome and coronary artery disease. 

Coronary Artery Disease. 2003

Efficacy and safety of faster aspart compared with insulin aspart both with insulin degludec in adults with T1D [poster]

2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [review]. 

Diabetes care. 2012

The safety of incretin-based therapies--review of the scientific evidence [review]. 

Journal of Clinical Endocrinology and Metabolism. 2011

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Journal of the American College of Cardiology. 2009

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Circulation. 2009

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [review]. 

Diabetes care. 2009

Derived time-in-range is associated with MACE in T2D: data from the DEVOTE Trial [abstract]. 

Diabetes. 2020